LUCD — Lucid Diagnostics Income Statement
0.000.00%
- $135.42m
- $186.08m
- $4.35m
Annual income statement for Lucid Diagnostics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.5 | 0.377 | 2.43 | 4.35 |
Cost of Revenue | |||||
Gross Profit | — | -0.085 | -3.24 | -3.55 | -2.75 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.28 | 27.9 | 56.5 | 50.9 | 55.6 |
Operating Profit | -8.28 | -27.4 | -56.2 | -48.5 | -51.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -8.28 | -28.1 | -56.2 | -52.7 | -45.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.28 | -28.1 | -56.2 | -52.7 | -45.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -8.28 | -28.1 | -56.2 | -52.7 | -45.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.28 | -28.1 | -56.2 | -52.7 | -53 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.224 | -0.804 | -1.55 | -1.26 | -0.947 |
Dividends per Share |